spacer
home > pmps > winter 2018 > the right excipient
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Right Excipient

The global empty hard capsules market is anticipated to increase at a compound annual growth rate of 7.2% and to reach $213 billion in revenues by 2022 (1). Over the past five years, about 12% of all prescription-based (Rx) and overthe- counter (OTC) pharmaceutical products were dosed with hard capsules, according to FDA documentation.

Despite being overlooked in the formulation of prescription drugs, the soft gels market is predicted to grow to $755 million by 2022 (2). This is mainly due to their popularity in the nutraceutical markets and added value in difficult Rx formulations, including very low-dose APIs (< 3mg), potent compounds, hormones and cytotoxic compounds (safe handling), oxygenlabile APIs, and, especially, poorly soluble or permeable APIs. As the market expands and new formulation technologies are adopted, selecting the right ingredient is essential to achieve optimum performance and functionality.

Choosing the Right Excipient

Favoured for its high functional capabilities, gelatine has been used in both hard and soft capsules in the pharma and nutraceutical industry for over 100 years. Capsule manufacturing started in 1834 thanks to gelatine, which has been the safe and only choice for decades. The first commercially feasible gelatine alternative entered the market in 2001: a soft gel shell alternative made of modified starches (hydroxypropyl starch) and carrageenans. Subsequently, hard gelatine capsule alternatives were commercialised, using hydroxypropyl methylcellulose (HPMC) as the main shell ingredient and carrageenans or gellan gum as gelling aids.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Bjorn Vergauwen is Principal Scientist at Rousselot. He currently coordinates R&D projects, aiming to unlock the unmet potential of gelatine. His main expertise relates to the biophysical and biochemical principles underpinning gelatine’s behaviour in food and pharma applications and to its use in dosage forms. Dr Vergauwen has a PhD in biochemistry from Ghent University, Belgium. Before joining Rousselot in 2014, he had several missions as Post-Doctoral Researcher at Ghent University where he conducted research in enzymology and structural biology for 17 years.
spacer
Dr Bjorn Vergauwen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Phenomenex Introduces bioZen Series for Characterization of Biotherapeutics

Torrance, Calif. (April 16, 2018) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces bioZen – a new series of LC solutions for bioseparations in pharmaceutical, biopharmaceutical and academic research. The series encompasses both proven and entirely new media spanning two particle platforms – core-shell and thermally modified fully porous – along with new biocompatible titanium hardware. The initial bioZen product line features seven chemistries for the UHPLC and HPLC characterization of biotherapeutics such as monoclonal antibodies, antibody-drug conjugates and biosimilars. The offering includes specific LC chemistries for the analysis of aggregates and total mAb, intact mass and fragments, peptide mapping and quantitation and glycan mapping.
More info >>

White Papers

Assessing the Integrity of Pharmaceutical Packaging Using the Sepha Blisterscan and Conventional Blue Dye Leak Testing Methods

Sepha Limited

A new whitepaper by a leading packaging expert from the University of Ulster, Dr Dorian Dixon, into the integrity of pharmaceutical packaging has established that existing methods for testing the seal integrity of blister packs are not as accurate as newer, technology based test equipment.
More info >>

 
Industry Events

BioPharm America 2018

5-6 September 2018, Hynes Convention Center

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement